(Q45925746)

English

CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.

scientific article published in September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Corinne Miceli-Richard

4

object named as

Corinne Miceli-Richard

0 references

Xavier Le Loët

7

object named as

Xavier Le Loët

0 references

Maxime Dougados

10

object named as

Maxime Dougados

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

5

object named as

Bernard Combe

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

Xavier Mariette

12

object named as

Xavier Mariette

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

author name string

Jérémie Sellam

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

Stéphanie Rouanet

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

Houria Hendel-Chavez

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

Corinne Miceli-Richard

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

Jean Sibilia

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

Jacques Tebib

8

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

Rosemary Jourdan

9

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

Yassine Taoufik

11

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

publication date

1 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

65

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

9

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

2253-2261

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

Rituximab: a new therapeutic alternative in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Cells of the synovium in rheumatoid arthritis. B cells

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases.

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Role of the CCL21 and CCR7 pathways in rheumatoid arthritis angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Lymphoid neogenesis in chronic inflammatory diseases.

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients.

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.38023

21 January 2018

Identifiers

10.1002/ART.38023

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23740460

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45925746&oldid=1561079187"